US Intervenes to Support Faltering Japanese Yen
By TopHolding Editorial · Tuesday, August 4, 2026 at 10:00 AM
The U.S. Treasury purchased Japanese yen for the first time since 1998 to support the currency. Meanwhile, reported pharma merger talks have analysts questioning the logic, and a new Spider-Man movie set a box office record.
The United States takes the rare step of intervening in currency markets to support a key ally. Elsewhere, a potential pharmaceutical mega-merger raises questions, and a superhero film breaks records.
US Government Buys Yen to Boost Value
The United States Treasury has intervened to support the Japanese yen, purchasing the currency for the first time since 1998. The move came after the yen-dollar exchange rate reached a 40-year low over the weekend, driven by concerns over Japan's government debt, low interest rates, and rising oil import costs.
The exact amount of the US purchase is unknown, but reports suggest it could be between $5 billion and $10 billion. The intervention is intended to prevent potential negative effects on the US economy. A primary concern was that Japan might sell its large holdings of US government bonds to raise funds to buy yen, which would increase borrowing costs for the US.
Analysts express skepticism about the long-term effectiveness of the intervention. They argue that a sustainable recovery for the yen would require Japan's central bank to raise interest rates more aggressively and for the government to reduce its debt. Higher rates would discourage the 'carry trade,'¹ a practice that has contributed to the yen's weakness.
Analysts Question Reported Pharma Merger Talks
A financial news report indicated that rival drugmakers AstraZeneca and Bristol Myers Squibb are in discussions for a merger that could be one of the largest in the industry's history. The combined company would have a market capitalization² of approximately $400 billion, making it the world's fourth-largest pharmaceutical firm. Neither company has commented on the report.
AstraZeneca's stock declined about 7% following the news, as investors and analysts expressed confusion over the potential deal's logic. AstraZeneca's business is currently experiencing strong growth, while Bristol Myers Squibb is expected to see a dip in performance next year as patents for some of its top medications expire.
A possible motivation for AstraZeneca is to expand its business in the United States, which already accounts for nearly half its revenue. A merger would also create the industry's largest portfolio of cancer drugs. However, such a combination would likely face significant antitrust scrutiny³ from regulators.
New Spider-Man Film Sets Box Office Record
The film "Spider-Man: Brand New Day" achieved the highest-grossing domestic opening weekend in box office history, earning $360 million. The figure narrowly surpasses the previous record held by "Avengers: Endgame," which was released in 2019.
The success of the new Spider-Man movie contributed to a record-breaking weekend for the entire North American box office, which generated a total of $430 million. The strong performance represents a significant win for the Marvel Cinematic Universe (MCU), which has seen some of its more recent films underperform both critically and commercially.
The six films in the MCU's 'Phase 5' series collectively grossed $3.65 billion, the lowest total for any phase in the franchise's history. Several recent releases also received low ratings. The record-setting debut of the new film comes as a positive turn for the franchise.
Bottom line for investors
The US intervention in currency markets highlights growing global economic instability and the interconnectedness of major economies, where a weak yen could impact US borrowing costs.
Key terms
- 1Carry trade: An investment strategy that involves borrowing a currency with a low interest rate and then investing those funds in an asset denominated in a currency with a high interest rate.
- 2Market capitalization: The total market value of a publicly traded company's outstanding shares, calculated by multiplying the share price by the number of shares in circulation.
- 3Antitrust scrutiny: An investigation by government agencies to determine if a proposed merger or business practice would unfairly reduce competition and harm consumers.